Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology, Inc. (PYXS)
:PYXS
PYXS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $6.18
Previous CloseN/A
Volume258.73K
Average Volume (3M)626.55K
Market Cap
$70.83M
Enterprise Value$97.07M
Total Cash (Recent Filing)-$19.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 09, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding61,590,416
10 Day Avg. Volume490,540
30 Day Avg. Volume626,547
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.62
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-48.54
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$7.25Price Target Upside590.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Pyxis Oncology News
PremiumCompany Announcements
Pyxis Oncology Highlights Strategic Focus on Lead Candidate
PremiumCompany Announcements
Pyxis Oncology Advances Cancer Therapeutics with MICVO
PremiumCompany Announcements
Pyxis Oncology Announces CMO Resignation and New Trials---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPyxis's streamlined focus on executing micvotabart pelidotin’s Ph 1 trial in squamous cell carcinoma of the head & neck is expected to maximize clinical investment and potential return.
Strategic PartnershipsThe Company has a clinical trial collaboration agreement with Merck for a combination therapy with Keytruda, targeting head and neck squamous cell carcinoma patients.
Bears Say
Financial PerformanceFor FY24, the company reported a net loss of $1.32 per share, compared to the consensus estimated net loss of $1.09 per share.
Market ChallengesShort interest stands at 16.6% of the float, indicating a significant portion of investors are betting against the stock.
---
Ownership Overview
10.74% Insiders
6.70% Mutual Funds
27.10% Other Institutional Investors
47.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PYXS FAQ
What was Pyxis Oncology, Inc.’s price range in the past 12 months?
Pyxis Oncology, Inc. lowest stock price was $0.98 and its highest was $6.18 in the past 12 months.
What is Pyxis Oncology, Inc.’s market cap?
Pyxis Oncology, Inc.’s market cap is $70.83M.
When is Pyxis Oncology, Inc.’s upcoming earnings report date?
Pyxis Oncology, Inc.’s upcoming earnings report date is May 09, 2025 which is in 42 days.
How were Pyxis Oncology, Inc.’s earnings last quarter?
Pyxis Oncology, Inc. released its earnings results on Mar 18, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.32 by -$0.3.
Is Pyxis Oncology, Inc. overvalued?
According to Wall Street analysts Pyxis Oncology, Inc.’s price is currently Undervalued.
Does Pyxis Oncology, Inc. pay dividends?
Pyxis Oncology, Inc. does not currently pay dividends.
What is Pyxis Oncology, Inc.’s EPS estimate?
Pyxis Oncology, Inc.’s EPS estimate is -0.3.
How many shares outstanding does Pyxis Oncology, Inc. have?
Pyxis Oncology, Inc. has 61,590,416 shares outstanding.
What happened to Pyxis Oncology, Inc.’s price movement after its last earnings report?
Pyxis Oncology, Inc. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.32. Following the earnings report the stock price went down -8.621%.
Which hedge fund is a major shareholder of Pyxis Oncology, Inc.?
Currently, no hedge funds are holding shares in PYXS
---
Pyxis Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (590.48% Upside)
$7.25 (590.48% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 289.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $174.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 10.5%
Last 30 Days ▼ 10.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.04%
12-Months-Change
Fundamentals
Return on Equity
-62.75%
Trailing 12-Months
Asset Growth
-9.52%
Trailing 12-Months
Company Description
Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
---
PYXS Stock 12 Month Forecast
Average Price Target
$7.25
▲(590.48% Upside)
Technical Analysis
Fate Therapeutics
―
Kala Pharmaceuticals
―
Cabaletta Bio
―
Nurix Therapeutics
―
Biohaven Ltd.
―
Best Analysts Covering PYXS
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-3.79%
reiterated a buy rating 9 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -3.79% per trade.
---